Volker Breu

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Martine Clozel, Volker Breu, Gillian A. Gray et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 668 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

Martine Clozel, Volker Breu, Kaspar F. Burri et al. · Nature · 1993 · 529 citations

Life Sciences, Pharmacology, Physiology +9

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo

Martine Clozel, Gillian A. Gray, Volker Breu et al. · Biochemical and Biophysical Research Communications · 1992 · 402 citations

Life Sciences, Pharmacology, Physiology +9

NF-κB Inhibition Ameliorates Angiotensin II–Induced Inflammatory Damage in Rats

Dominik N. Müller, Ralf Dechend, Eero Mervaala et al. · Hypertension · 2000 · 401 citations

Medicine, Nephrology, Pharmacology +16

Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study

Peter Vajkoczy, Bernhard Meyer, Stefan Weidauer et al. · Journal of neurosurgery · 2005 · 302 citations

Medicine, Neurosurgery, Pharmacotherapy +14